A phase I study of PXL 770 in healthy volunteers

Trial Profile

A phase I study of PXL 770 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Proof of concept
  • Sponsors Poxel
  • Most Recent Events

    • 27 Jan 2017 According to a Poxel media release, the company anticipates to continue the study during the second half of this year.
    • 15 Sep 2016 According to a Poxel media release, during the study the company observed a different metabolic pattern in humans compared to animals that were treated with PXL770. Therefore, based on regulatory guidelines, Poxel will need to further evaluate the profile of the metabolites, prior to starting the second part of the phase I study. As a result of this additional preclinical work, the start of the second part of the Phase Ib study will be delayed until 2017.
    • 20 Jun 2016 Results from the first stage of the study (n=64) published in a Poxel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top